Goldman Sachs
IDYA icon

Goldman Sachs’s IDEAYA Biosciences IDYA Stock Holding History

Goldman Sachs’s Portfolio IDYA Stock Details IDYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$55.2M Sell
1,655,617
-115,249
-7% -$3.87M 0.01% 1500
2025
Q4 		$61.2M Buy
1,770,866
+537,753
+44% +$17.1M 0.01% 1338
2025
Q3 		$33.6M Buy
1,233,113
+4,929
+0.4% +$119K ﹤0.01% 1768
2025
Q2 		$25.8M Buy
1,228,184
+411,962
+50% +$7.9M ﹤0.01% 1897
2025
Q1 		$13.4M Sell
816,222
-941,911
-54% -$20.1M ﹤0.01% 2422
2024
Q4 		$45.2M Buy
1,758,133
+888,950
+102% +$25.2M 0.01% 1387
2024
Q3 		$27.5M Buy
869,183
+192,449
+28% +$7.3M ﹤0.01% 1768
2024
Q2 		$23.8M Buy
676,734
+257,835
+62% +$10.2M ﹤0.01% 1748
2024
Q1 		$18.4M Buy
418,899
+140,733
+51% +$6.05M ﹤0.01% 1910
2023
Q4 		$9.9M Sell
278,166
-141,856
-34% -$4.23M ﹤0.01% 2547
2023
Q3 		$11.3M Buy
420,022
+29,943
+8% +$759K ﹤0.01% 2288
2023
Q2 		$9.17M Buy
390,079
+198,350
+103% +$4.08M ﹤0.01% 2535
2023
Q1 		$2.63M Buy
191,729
+30,898
+19% +$515K ﹤0.01% 3635
2022
Q4 		$2.92M Buy
160,831
+49,110
+44% +$826K ﹤0.01% 3632
2022
Q3 		$1.67M Buy
111,721
+10,730
+11% +$139K ﹤0.01% 4118
2022
Q2 		$1.39M Sell
100,991
-90,996
-47% -$1.01M ﹤0.01% 4359
2022
Q1 		$2.15M Buy
191,987
+87,482
+84% +$1.29M ﹤0.01% 4198
2021
Q4 		$2.47M Buy
104,505
+48,621
+87% +$1.13M ﹤0.01% 4071
2021
Q3 		$1.42M Buy
55,884
+18,410
+49% +$430K ﹤0.01% 4473
2021
Q2 		$786K Buy
37,474
+3,054
+9% +$62.7K ﹤0.01% 4937
2021
Q1 		$809K Buy
34,420
+5,036
+17% +$97.2K ﹤0.01% 4766
2020
Q4 		$411K Buy
29,384
+19,060
+185% +$258K ﹤0.01% 4724
2020
Q3 		$130K Sell
10,324
-147,931
-93% -$1.83M ﹤0.01% 5031
2020
Q2 		$2.25M Buy
158,255
+131,892
+500% +$1.04M ﹤0.01% 3375
2020
Q1 		$109K Buy
26,363
+6,506
+33% +$46.1K ﹤0.01% 4921
2019
Q4 		$149K Sell
19,857
-42,841
-68% -$306K ﹤0.01% 4976
2019
Q3 		$564K Sell
62,698
-55,709
-47% -$425K ﹤0.01% 4388
2019
Q2 		$1.18M Buy
+118,407
New +$1.29M ﹤0.01% 3887

Other funds holding IDYA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Goldman Sachs's IDYA Position: Q1 2026 in Review

Goldman Sachs reduced its IDEAYA Biosciences (IDYA) stake by 6.5% in Q1 2026, selling an estimated $3.87M and leaving 1,655,617 shares worth $55.2M. The position accounts for 0.01% of the portfolio, ranked #1500.

Goldman Sachs first reported a position in IDYA in Q2 2019 and has held it in 28 quarters since. The position peaked at $61.2M in Q4 2025. 253 funds tracked by Wall St. Rank hold IDYA as of Q1 2026.

  • Goldman Sachs held 1,655,617 shares of IDEAYA Biosciences worth $55.2M as of Q1 2026.
  • Goldman Sachs sold 115,249 IDEAYA Biosciences shares in Q1 2026, an estimated $3.87M.
  • IDEAYA Biosciences made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1500 holding.
  • Goldman Sachs first reported a position in IDEAYA Biosciences in Q2 2019 and has held it in 28 quarters since.
  • Goldman Sachs's IDEAYA Biosciences position peaked at $61.2M in Q4 2025.
  • 253 funds tracked by Wall St. Rank held IDEAYA Biosciences as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.